natgillin/translations-raw huggingface dataset:
in part (c), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:117 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:116; 
(c) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 111i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 110;
the wt human extracellular domain of PSMA (SEQ ID NO: 447) on the cell surface; 
(i) ljudsku izvanstaničnu domenu PSMA divljeg tipa sa SEQ ID:447 na površini stanice;
A combination of a compound of formula (I), or a pharmaceutically acceptable salt thereof: and one or more additional therapeutic agents. 
Kombinacija spoja formule (I), ili njegove farmaceutski prihvatljive soli:
A process for obtaining a microencapsulated bacterial consortium, according to claim 10, wherein the drying is carried out by a spray-dryer, at an inlet temperature of 150 °C, and at an outlet temperature of 80 °C, with a feed rate of 22 mL/min. 
Postupak dobivanja mikroenkapsuliranog bakterijskog konzorcija, prema zahtjevu 10, pri čemu se sušenje izvodi sušilom u spreju, pri ulaznoj temperaturi od 150 oC, te pri izlaznoj temperaturi od 80 oC, uz brzinu protoka od 22 mL/min.
The method of claim 3 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau. 
Formulacija u skladu sa patentnim zahtjevom &8 gdje je interferon odabran od interferona alfa 2B, pegiliranog interferona alfa, konsenzusnog interferona, interferona alfa 2A, i limfoblastičnog interferona tau.
If the hot wire current reaches the load and returns through the neutral without leakage to ground, there is no magneto motive force in the core of said transformer to induce a secondary current. 
Ako struja iz faznog voda poteče prema nul-vodu, bez odvoda prema zemlji, nema magnetomotorne sile u jezgri spomenutog transformatora koja bi inducirala struju na sekundaru.
The pharmaceutical composition of claim 1 wherein the compound of formula IIB is a compound of formula IIC: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav prema patentnom zahtjevu 1 pri čemu spoj formule IIB je spoj formule IIC: ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili ester, pri čemu:
An aqueous pharmaceutical composition with a pH between 3.4 and 4.6 comprising insulin glargine for use in a method of treating Type I and Type II Diabetes Mellitus, wherein the composition comprises 270 - 330 U/mL of insulin glargine. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za liječenje dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
Oligosaccharides do not include bicyclic groups that are formed by fusing a monosaccharide to a benzene ring, a cyclohexane ring, or a heterocyclic ring. 
Oligosaharidi ne uključuju bicikličke grupe koje nastaju spajanjem monosaharida na benzenski prsten, cikloheksanski prsten ili heterociklički prsten.
is and R3 are independently selected from the group consisting of 
R2 i R3 se neovisno bira iz skupine koju čine: f
The process of claim 1, wherein the calcium carbonate has a particle size from 1 to 15 nm. The process of claim 1, wherein the calcium carbonate has a particle size from 2 to 10 nm. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu kalcij karbonat ima veličinu čestica od 0.5 do 50 µm, od 1 do 15 µm, poželjno od 2 do 10 µm, najpoželjnije 3 do 5 µm.
A computer system for blocking specific instructions from being executed by a processor, comprising: a memory; a processor in communication with the memory, the processor comprising an instruction fetching element for fetching instructions from memory and one or more execution elements for executing fetched instructions; 
Računalni sustav za blokiranje specifičnih naredbi za izvršavanje od strane procesora, obuhvaća: memoriju; procesor u komunikaciji s memorijom, procesor obuhvaća element za dohvaćanje naredbe za dohvaćanje naredbi iz memorije i jedan ili više izvršnih elemenata za izvršavanje dohvaćenih naredbi; pri čemu je računalni sustav konfiguriran za izvođenje metode u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
Example 22. A device according to any of examples 1-21, wherein one or more of the fluid channel (23) and guiding passages (10,11) is provided by a detachable wall member positioned inside the tubular member. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 2 - 22, kod kojega su jedan ili više kanala za fluid (23) i prolaza za vođenje (10, 11) snabdjeveni s elementom stijenke koji se može odvojiti i koji je stavljen u unutrašnjost cijevnog elementa.
In a first aspect of the seventh embodiment, the concentration of the colistimethate sodium ranges from 80 to 200 mg A/mL. 
Uređaj sukladno patentnom zahtjevu 1 ili 2, pri čemu je koncentracija sulfometiliziranog polimiksina u rasponu od 80 do 200 mg A/mL.
The energy savings system of claim 1, wherein the system further comprises a means for communicating with at least one computing device. 
Sustav za uštedu energije iz zahtjeva 1, gdje sustav obuhvaća jedan način za komuniciranje s najmanje jednim računalnim uređajem.
The pharmaceutical composition according to any of claims 1 to 4, further comprising at least one suitable adjuvant, selected from the group comprising 1018 ISS, aluminium salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, Imiquimod, ImuFact IMP321, IS Patch, ISCOMATRIX, Juvlmmune, LipoVac, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PepTel vector system, PLG microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, YF-17DBCG, Aquila's QS21 stimulon, Ribi's Detox. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 4, koji nadalje uključuje najmanje jedan prikladan adjuvans odabran iz skupine koja sadrži 1018 ISS, aluminijeve soli, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, imikvimod, ImuFact IMP321, IS Patch, ISCOMATRIX, JuvImmune, LipoVac, MFS59, monofosforilni lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, vektorski sustav PepTel, PLG mikro-čestice, resikvimod, SRL172, Virosomes 1 druge čestice slične virusima, YF-17DBCG, stimulon QS21 kompanije Aquila Biotech, Ribi's Detox.
An isolated nucleic acid molecule: encoding at least one isolated IL-23p19 antibody according to any of claims 1-4; or 
Izolirana molekula nukleinske kiseline koja kodira najmanje jedno izolirano IL-23p19 antitijelo prema bilo kojem od patentnih zahtijeva 1-7 1 10-14.
punching for making one or more of said data sheets (4) into a desired size; and 
- < rezanje jednog ili više navedenih podatkovnih listova (4) na željenu veličinu i
The TGFß antagonist of claim 6, wherein said antibody is a humanized antibody that comprises one or more CDRs of 1D11. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 6, naznačen time što navedeno protutijelo je humanizirano protutijelo koje sadrži jednu ili više CDR-ova od 1D11.
The method according to claim 10, wherein a reaction mixture the guanidine derivative and diamine is kept at the first temperature for 1 to 3 hours and at the second temperature for 1 to 8 hours. 
Postupak u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da se reakcijska smjesa održava pri prvoj temperaturi 1 do 3 sata, a pri drugoj temperaturi 1 do 8 sati.
The apparatus of claim 11, wherein one end of the valve is connected to a hose attached to a water supply, and the other end is threaded to the housing. The apparatus of claim 1, wherein each hole at the second end of the housing extends through an outer surface of the housing, the outer surface opposing the opening at the first end of the housing. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time, da se svaka rupa od većeg broja rupa (26) na drugom kraju (B) kućišta proteže kroz vanjsku površinu kućišta, pri čemu se vanjska površina na drugom kraju kućišta nalazi na suprotnom kraju kućišta od otvora na prvom kraju (A) kućišta (12).
A UTI fusion protein as defined in any one of claims 1, 2 and 3 for use in treating pancreatitis, including endoscopy-induced pancreatitis and acute pancreatitis; arthritis, SARS, systemic inflammatory response syndrome, acute circulatory failure, sepsis, hepatitis, appendicitis, colitis, organ failure, organ damage, including damage to pancreas, kidney or lung; reperfusion injury, Stevens-Johnson syndrome, toxic epidermal necrolysis, shock, ischemic injuries, acute lung injury, including lung injury caused by acute aortic dissection; asthma, lung inflammation, pneumonia, including ventilator-associated pneumonia; disseminated intravascular coagulation or acute respiratory distress syndrome. 
UTI-fuzijski protem koji je definiran u bilo kojem od zahtjeva 1, 2 i 3, naznačen time, da se upotrebljava u liječenju pankreatitisa, uključujući pankreatitis induciran endoskopijom 1 akutni pankreatitis; artritisa, SARS-a, sindroma sustavne upalne reakcije, akutnog cirkulacijskog zastoja, sepse, hepatitisa, apendicitisa, kolitisa, zatajenja organa, oštećenja organa, uključujući oštećenja na gušterači, bubregu ili plućima; reperfuzijske ozljede, Stevens-Johnsonovog sindroma, toksične epidermalne nekrolize, šoka, ishemijskih ozljeda, akutne ozljede pluća, uključujući ozljedu pluća koja je prouzročena akutnom disekcijom aorte; astme, upale pluća, pneumonije, uključujući pneumoniju povezanu s ventilatorom; diseminirane intravaskularne koagulopatije ili sindroma akutnog respiratornog poremećaja (ARDS-a).
A composition comprising the antibody of any one of claims 1 to 5, 9 or 10, the polynucleotide of claim 6, the vector of claim 7 or the cell of claim 8, wherein the composition is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier; 
Pripravak, naznačen time, da sadržava antitijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 5, 9 ili 10, polinukleotid u skladu s patentnim zahtjevom 6, vektor u skladu s patentnim zahtjevom 7 ili stanica u skladu s patentnim zahtjevom 8, pri čemu je pripravak (i) farmaceutski pripravak 1 nadalje sadržava farmaceutski prihvatljivi nosač;
contacting IV with a silyl chloride (Ra)3SiCl and at least one base in a non-polar aprotic solvent to afford (V), and subsequently adding sulfonylchloride Rb S(O)2Cl to afford VI, wherein Ra is independently in each occurrence C1-6 alkyl or phenyl and Rb is selected from C1-4 alkyl or phenyl, optionally substituted with 1 to 3 groups independently selected from C1-3 alkyl, halogen, nitro, cyano, or C1-3 alkoxy; 
(d) dovođenje u doticaj IV sa sililkloridom (R*)3SiC1 i s najmanje jednom bazom u nepolarnom aprotičkom otapalu, kako bi se dobio (V), i uzastopno dodavanje sulfonilklorida R"S(O),CL, kako bi se dobio VI, pri čemu je R* neovisno u svakom pojavljivanju C,4 alkil ili fenil i R" je odabran od C,, alkila ili fenila, opcionalno supstituiranog s 1 do 3 skupine koje su neovisno odabrane od C1.3 alkila, halogena, nitro, cijano ili C;.3 alkoksi;
a nitrosation reaction to obtain: 
IV. reakciji nitrozacije, čime se dobije:
This invention relates to processes for the production of 3-oxo-pregnane-21,17-carbolactones, in particular processes for the production of 3-oxo-17a-pregnane-21,17-carbolactones. 
HR P20180454 T1 HR P20180454 T1 PATENTNI ZAHTJEVI 1. > Postupak za proizvodnju 3-okso-pregn-4-en-21,17-karbolaktona s formulom IIIa llka 5
The process of claim 13, further comprising removing at least some of the free diphenylmethane diisocyanate from the prepolymer mixture forming the pre-elastomer mixture. A process for making a polyurethane elastomer comprising: 
Postupak prema zahtjevu 13, naznačen time, da so nadalje sastoji od uklanjanja najmanje nekih od slobodnih difenilmetan diizocijanata iz smjese predpolimera stvarajući smjesu predelastomera.
The affinity to CEA may be to any one of its known epitopes such as the GOLD-2 epitope. In a particularly preferred embodiment, the targeting agent is a chimeric monoclonal antibody having affinity to CEA. 
Postupak prema zahtjevu 10, naznačen time da je ciljano sredstvo kimerno monoklonsko protutijelo koje ima afinitet prema CEA, i/ili pri čemu je fluorokrom spoj formule (IV):
Pressure tank, especially made of four shells, creating a toroidal tank, comprising connected together shells, and equipped with connector pipes for fittings, brackets for fixing the tank and cover, fittings cover, central coupler with holes and central bush, the tank comprising: 
PATENTNI ZAHTJEVI Spremnik pod pritiskom, posebno izrađen od četiri omotača koji stvaraju prstenasti spremnik, koji sadrži međusobno spojene omotače i opremljen je sa spojnim cijevima za pribor, spojnice za pričvršćivanje spremnika i poklopca, opreme poklopca, središnjeg sprežnika sa provrtima i centralne cjevčice, pri čemu spremnik sadrži:
Fine iron powder 
Sitni željezni prah
optionally molding the obtained mixture to the desired form. 
(ili) izbornom oblikovanju dobivene smjese u željeni oblik.
reacting an intermediate of formula (VI-a) or (VI-b) wherein W2 represents a suitable leaving group, with a suitable primary or secondary amine HNR4R5, optionally in the presence of a suitable solvent 
d) reakcije intermedijera sa formulom (VI-a) ili (VI-b) pri čemu W> predstavlja prikladnu odlaznu skupinu, sa pogodnim primarnim ili sekundarnim aminom HNR*R-, proizvoljno u prisutnosti pogodnog otapala
The immunconjugate of claim 1, wherein the antibody comprises a full-length heavy chain having the amino acid sequence of SEQ ID NO:88, and a full-length light chain having the amino acid sequence of SEQ ID NO:87. 
obuhvaća jaki lanac pune duljine, koji ima aminokiselinsku sekvencu SEQ ID NO:88 i slabi lanac pune duljine, koji ima aminokiselinsku sekvencu SEQ ID NO:87; ili
Another aspect of the disclosure concerns apparatus for estimating the fraction of fetal DNA in DNA obtained from a bodily fluid of a pregnant individual. 
Postupak procjene frakcije fetalne DNK u DNK dobivenoj iz tjelesne tekućine trudne osobe, te postupak sadrži:
The apparatus of claim 11 or 12, wherein the L1 block has L1 signaling information for signaling the data slice. 
Uređaj prema zahtjevu 11 ili 12, naznačen time, što LI blok ima LI signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
• at least one second stop tooth integrally connected to a second tongue that is elastically deformable and integrally connected to said slider (18); 
• najmanje jedan drugi granični zub, integralno spojen s drugim jezičcem koji se može elastično deformirati i integralno je spojen s navedenim kliznikom (18);
In an embodiment of one of the methods described above the biological sample is chosen from the group consisting of blood, serum and plasma. 
Aflibercept za uporabu u liječenju pacijenta prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što se biološki uzorak bira iz skupine koju čine krv, serum i plazma.
The compound of claim 7, wherein (R8)b is an iso-propyl group, a tert -butyl group or a -halo selected from the group of -F, -Cl, -Br and -I. 
Spoj prema zahtjevu 7, naznačen time da (R8)b je izopropil skupina, tert-butil skupina ili -halogen odabran iz skupine koja sadrži -F, -Cl, -Br i -I.
The measuring may entail determining the amount or concentration of caspase-3 or nucleic acid encoding caspase-3. The invention provides methods for informing an MS patient of an increased risk of developing a secondary autoimmune disease following lymphocyte depletion, comprising the steps of obtaining or ascertaining information on interleukin-21 (IL-21) in a blood sample from the MS patient, wherein elevated IL-21 compared to a subject without an autoimmune disease indicates that the patient is at increased risk of developing a secondary autoimmune disease compared to MS patients without elevated IL-21; and informing the patient of an increased risk or lack thereof. 
Postupak za odabir pacijenta s multiplom sklerozom (MS) kojem je potrebno pojačano praćenje razvoja sekundarne autoimune bolesti nakon terapije osiromašenja limfocita, comprising: mjerenje razine interleukin-21 (IL-21) u uzorku krvi od pacijenta koji ima MS; i usporedbu razine IL-21 u uzorku od pacijenta koji ima MS sa razinom IL-21 od subjekta bez autoimune bolesti, pri čemu povišena razina IL-21 kod navedenog pacijenta u usporedbi sa subjektom bez autoimune bolesti pokazuje da pacijent ima potrebu za pojačanim praćenjem razvoja sekundarne autoimune bolesti u usporedbi s MS pacijentima bez povišene razine IL-
The intragastric balloon of claim 1, wherein before the expandable foaming substances have cured the intragastric balloon is adapted to be swallowed. 
Intragastrički balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu se, prije no što tvari očvsnu, intragastrički balon (10) se prilagodi da proguta
The method for producing the crystal according to claim 30, wherein the solvent is selected from the group consisting of ethers, ketones, esters, alcohols, water, and a mixture solvent thereof. 
Postupak prema zahtjevu 22 ili 23, naznačen time što je otapalo je odabrano iz skupine koja se sastoji od etera, ketona, estera, alkohola, vode i njihove smjese otapala.
The system as claimed in claim 18, the computer being local. The system as claimed in claim 22, the final orientation of the solar collectors being determined autonomously by the computer. 
Sustav prema bilo kojem od patentnih zahtjeva 8 do 10, naznačen time što je računalo lokalno i orijentacija kolektora se određuje autonomno pomoću računala.
Filtration gave the intermediate 19 as a white solid (0.23 g, 23%). 
Filtracija je dala Intermedijer 19 kao bijelu čvrstu supstancu (0.23 g, 23%).
A fan assembly as claimed in claim 9 or claim 10, wherein the second silencing member (74) comprises acoustic foam. 
Ventilatorski sustav prema zahtjevu 9 ili zahtjevu 10, gdje drugi dio za stišavanje buko (74) obuhvaća akustičnu pjenu.
The compound of claim 1, selected from the group consisting of: and or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, koji se bira iz skupine koju čine: O N
The method according to claim 11, wherein the antibody is selected from the group consisting of an antibody against MUC1; an antibody against HER2; and an antibody against EGFR. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se protutijelo bira iz skupine koju čine protutijelo protiv MUCI; protutijelo protiv HER2; i protutijelo protiv EGFR.
A blended wax according to claim 2, the blended wax comprising four wax cuts and wherein the first wax cut comprises a melting point in the range 48-50 °C, the second wax cut comprises a melting point in the range 54-57 °C, the third wax cut comprises a melting point in the range 60-62 °C and the fourth wax cut comprises a melting point in the range 65-68 °C. 
Miješani vosak u skladu s patentnim zahtjevom 2, naznačen time što miješani vosak sadrži četiri reza voska, te što prvi rez voska ima talište u rasponu od 48-50 *C, gdje drugi rez voska ima talište u rasponu od 54-57 "C, gdje treći Tez voska ima talište u rasponu od 60-62 "C, te gdje četvrti rez voska ima talište u rasponu od 65-68 *C.
wherein R1 is hydrogen or a nitrogen protecting group, as defined above, and R4 is an CO-activating group, as defined below, reacting the compound according to formula (4), or salt thereof, with a biphenylic compound to obtain a compound according to formula (5) 
gdje R1 je vodikova ili dušikova zaštitna skupina i R4 je CO-aktivacijska skupina; b) reakcija spoja prema formuli (4) ili njegove soli, s bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (5) ili njegova sol: pa i, o
In an analogous manner, 31-O-(D-allosylcarbonyl)rapamycin was also prepared. 
Na analogan način, pripremljen je 31-O-(D-alozilkarbonil)rapamicin.
The method of claim 3, wherein the non-selective a 1 /a2 adrenergic receptor agonist is selected from epinephrine, norepinephrine, isoproterenol, dipivefrin, pseudoephedrine, mephentermine and combinations thereof. 
Agonist za uporabu u skladu sa zahtjevom 3, naznačen time što je ne-selektivni agonist alfa 1/alfa 2 adrenergijskog receptora odabran od epinefrina, norepinefrina, izoproterenola, dipivefrina, pseudoefedrina, mefentermina i njihovih kombinacija.
Sodium metabisulfite and butylated hydroxyl anisole (BHA) were used as antioxidants in this study. 
U ovoj studiji su kao antioksidanti korišteni natrijev metabisulfit i butilirani hidroksil anizol (BHA).
The rodent cell of claim 17, wherein the nucleic acid sequence encoding a chimeric human/rodent CD8a polypeptide encodes a chimeric human/mouse CD8a polypeptide and is operably linked to an endogenous mouse CD8a promoter and regulatory sequences, and the nucleic acid sequence encoding a chimeric human/rodent CD8B polypeptide encodes a chimeric human/mouse CD8B polypeptide and is operably linked to an endogenous mouse CD8B promoter and regulatory sequences. 
Miš prema zahtjevu 5, naznačen time, da je nukleotidna sekvenca koja kodira kimerni ljudski/mišji CD4 polipeptid, radno povezana s endogenim mišjim CD4 promotorom i regulacijskim sekvencama, ili time, da je sekvenca nukleinske kiseline koja kodira ljudski/mišji CD8a polipeptid, radno povezana s mišjim CD8a promotorom i regulacijskim sekvencama, a sekvenca nukleinske kiseline koja kodira ljudski/mišji CD8B polipeptid je radno povezana s endogenim mišjim CD8B promotorom i regulacijskim sekvencama.
wherein B1a represents a phenyl group, a substituted phenyl group (wherein the substituent(s) represent 1 to 3 groups independently selected from substituent group a4), a 5-membered aromatic heterocyclyl group, or a substituted 5-membered aromatic heterocyclyl group (wherein the substituent(s) represent 1 to 3 groups independently selected from substituent group a4), 
(ila) gdje B'* predstavlja fenil skupinu, supstituiranu fenil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata a4, 5-eročlanu aromatsku heterocikličku skupinu, ili supstituiranu 5-eročlanu aromatsku heterocikličku skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata a4,
cloning a cDNA population derived from the mRNA isolated in step (c) into an expression vector and expressing the cDNA in a cell-line of choice; and 
(d) kloniranje CDNA populacije dobivene iz mRNA izolirane u koraku (c) u ekspresijski vektor i eksprimiranje ekspresijskog vektora u staničnoj liniji; te
In this described embodiment, these passages are provided for example by forming a “deep undulation” 27 on the lower edge 28 of the upper 13, so that the stitched seam 17 a joins only the crests 28 a of said “deep undulation” 27 to the membrane 15 and to the insole 16 . 
U tom opisanom utjelovljenju, takvi se prolazi dobivaju oblikovanjem "dubokih valova" 27 na donjem rubu 28 gornjišta 13, tako da šavovi 17a spajaju samo brjegove 284 navedenih "dubokih valova" 27 s membranom 15 i unutarnjim potplatom 16.